Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ganz

Showing results (31-40 of 85) with videos related to

Pageof 9
Sort By:
Medical Care|July 25, 2006
Community preferences for health states associated with intimate partner violenceEve Wittenberg, Erika L Lichter, Michael L Ganz, et al.
American Health & Drug Benefits|May 4, 2017
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United StatesJoseph Lee, Ryan Pelkey, Julieanna Gubitosa, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 11, 2018
Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 YearsQian Li, Rahul Ganguly, Michael L Ganz, et al.
Current Medical Research and Opinion|September 21, 2016
Real-world characteristics of elderly patients with overactive bladder in the United StatesMichael L Ganz, Jieruo Liu, Kelly H Zou, et al.
Advances in Therapy|September 24, 2014
Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort studyAbhishek S Chitnis, Michael L Ganz, Nicole Benjamin, et al.
The Milbank Quarterly|September 17, 1998
Social epidemiology and the fundamental cause concept: on the structuring of effective cancer screens by socioeconomic statusB G Link, M E Northridge, J C Phelan, et al.
Human Vaccines & Immunotherapeutics|December 16, 2024
Retrospective analysis of health and economic burden among commercially-insured individuals diagnosed with invasive meningococcal disease in the United StatesOscar Herrera-Restrepo, Marta Kwiatkowska, Samuel Huse, et al.
Inflammatory Bowel Diseases|March 15, 2016
The Economic and Health-related Impact of Crohn's Disease in the United States: Evidence from a Nationally Representative SurveyMichael L Ganz, Rebecca Sugarman, Rosa Wang, et al.
Current Medical Research and Opinion|October 12, 2017
The burden of severe hypoglycemia in type 1 diabetesJieruo Liu, Rosa Wang, Michael L Ganz, et al.
Journal of Medical Economics|July 3, 2015
Prevalence and healthcare costs of obesity-related comorbidities: evidence from an electronic medical records system in the United StatesQian Li, Steven W Blume, Joanna C Huang, et al.
Pageof 9

Showing results (31-40 of 85) with videos related to

Sort By:
Pageof 9
Medical Care|July 25, 2006
Community preferences for health states associated with intimate partner violenceEve Wittenberg, Erika L Lichter, Michael L Ganz, et al.
American Health & Drug Benefits|May 4, 2017
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United StatesJoseph Lee, Ryan Pelkey, Julieanna Gubitosa, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 11, 2018
Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 YearsQian Li, Rahul Ganguly, Michael L Ganz, et al.
Current Medical Research and Opinion|September 21, 2016
Real-world characteristics of elderly patients with overactive bladder in the United StatesMichael L Ganz, Jieruo Liu, Kelly H Zou, et al.
Advances in Therapy|September 24, 2014
Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort studyAbhishek S Chitnis, Michael L Ganz, Nicole Benjamin, et al.
The Milbank Quarterly|September 17, 1998
Social epidemiology and the fundamental cause concept: on the structuring of effective cancer screens by socioeconomic statusB G Link, M E Northridge, J C Phelan, et al.
Human Vaccines & Immunotherapeutics|December 16, 2024
Retrospective analysis of health and economic burden among commercially-insured individuals diagnosed with invasive meningococcal disease in the United StatesOscar Herrera-Restrepo, Marta Kwiatkowska, Samuel Huse, et al.
Inflammatory Bowel Diseases|March 15, 2016
The Economic and Health-related Impact of Crohn's Disease in the United States: Evidence from a Nationally Representative SurveyMichael L Ganz, Rebecca Sugarman, Rosa Wang, et al.
Current Medical Research and Opinion|October 12, 2017
The burden of severe hypoglycemia in type 1 diabetesJieruo Liu, Rosa Wang, Michael L Ganz, et al.
Journal of Medical Economics|July 3, 2015
Prevalence and healthcare costs of obesity-related comorbidities: evidence from an electronic medical records system in the United StatesQian Li, Steven W Blume, Joanna C Huang, et al.
Pageof 9